Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 148
- Registration Number
- NCT05884801
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05860530
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05851027
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT05830045
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05829616
- Locations
- 🇨🇳
The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, Beijing, China
A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05823285
- Locations
- 🇨🇳
Fudan Zhongshan Hospital, Shanghai, Shanghai, China
Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT05823246
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳The First Hospital of Jilin University, Changchun, Jilin, China
A Study of Olanzapine in Patients With Acute Agitation
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 318
- Registration Number
- NCT05803642
A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05802342
A Phase I Study of QL1604 for Advanced Solid Tumors
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 71
- Registration Number
- NCT05801094
- Locations
- 🇨🇳
The First Affliated Hospital of Nanchang University, Nanchang, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath